<DOC>
	<DOC>NCT00111683</DOC>
	<brief_summary>In this study participants with relapsed/refractory leukemia will be given MK-0457 in sequential cohorts and with varying treatment duration to determine the maximum tolerated dose (MTD) for MK-0457.</brief_summary>
	<brief_title>MK0457 in Patients With Leukemia (0457-003)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia, B-Cell</mesh_term>
	<criteria>Part 1: Patients with relapsed/refractory acute myelogenous leukemia (AML), poor risk myelodysplastic syndrome (MDS), Bcell acute lymphocytic leukemia (ALL), myeloproliferative diseases, or chronic myelogenous leukemia (CML) in blast crisis Part 2: Acute myelogenous leukemia (with FLT3 mutation ), and myeloproliferative diseases only At least 2 weeks since the last cytotoxic therapy Acceptable renal and hepatic function Ambulatory, capable of all selfcare, and out of bed for more than 50% of waking hours More than 2 months since autologous bone marrow or peripheral blood stem cell transplantation Not fully recovered from previous antileukemia therapy Previous allogeneic bone marrow transplant Uncontrolled congestive heart failure Myocardial infarction within the last 3 months Active or uncontrolled infection Pregnancy or lactation Currently active second malignancy, other than nonmelanoma skin cancer History of hepatitis B or C, known HIV positivity, or AIDS related illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Myelodysplastic Syndrome[Refractory Anemia with</keyword>
	<keyword>Excess Blasts-1 or 2 (WHO Classification)]</keyword>
	<keyword>Chronic Myelogenous Leukemia in blast crisis</keyword>
</DOC>